

Public Health Service

Food and Drug Administration Rockville, MD 20857

NDA 21-928

Pfizer Inc 50 Pequot Avenue New London, CT 06320

Attention: Michael J. Page, B.Sc.

Director, Worldwide Regulatory Strategy

Worldwide Regulatory Affairs and Quality Assurance

Dear Mr. Page:

Please refer to your new drug application (NDA) dated November 9, 2005, received November 10, 2005, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Chantix® (varenicline) 0.5 mg and 1 mg Tablets.

We acknowledge receipt of your submissions dated January 13, February 3, 7, 9, and 13, March 3, 8, 10, 14(2), 15, 23, 24, 27, 29, and 31, April 7, 11, and 20, and May 1, 4, and 10, 2006.

This new drug application provides for the use of Chantix® (varenicline) 0.5 mg and 1 mg Tablets as an aid to smoking cessation treatment.

We have completed our review of this application, as amended, and it is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling text for the package insert and the patient package insert submitted May 10, 2006, and further modified as agreed upon in our conversations of that date, and to the immediate container and carton labeling submitted April 11, 2006, and modified as documented in your submission of May 10, 2006. Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "FPL for approved NDA 21-928." Approval of this submission by FDA is not required before the labeling is used.

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and



effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We are waiving the pediatric study requirement for ages 0 to 11 years and deferring pediatric studies for ages 12 through 16 years, inclusive, for this application.

Your deferred pediatric studies required under section 2 of the Pediatric Research Equity Act (PREA) are considered required postmarketing study commitments. The status of these postmarketing studies shall be reported annually according to 21 CFR 314.81. These commitments are listed below.

1. To conduct a study to determine the multiple-dose pharmacokinetics of varenicline in pediatric patients in order to determine the appropriate doses for efficacy and safety evaluations in adolescent smokers, ages 12 through 16, inclusive, to determine the adverse event profile in adolescent patients, and to establish whether there is any age group (or weight group) for whom varenicline is so poorly tolerated that its utility as an aid to smoking cessation treatment should not be evaluated in that group.

Final Report Submission: by November 10, 2007

2. To conduct a study to determine whether varenicline, as part of an overall smoking cessation program, is effective in achieving and maintaining smoking cessation in tobacco-addicted adolescents, ages 12 through 16, inclusive, to determine a safe and effective dose, and to document the ability of treating physicians to select appropriate patients. You will need to develop a means for determining reliable criteria for appropriate patient selection of tobacco-addicted teens so that teenage smokers who are not addicted will not be recruited, and so that labeling can convey these criteria to physicians who may wish to use the drug in adolescents.

Final Report Submission: by May 10, 2011

We remind you of your postmarketing study commitment in your submission dated May 10, 2006. This commitment is listed below.

3. To conduct a prospective epidemiologic cohort study in pregnant women who are smokers and who are exposed to varenicline at the time of conception or any time during pregnancy. This information will be used to assess the potential risk to the fetus and/or live born infant.

Protocol Submission: by November 10, 2006

Study Start: by May 10, 2007 Final Report Submission: by May 10, 2011

Submit final study reports to this NDA. For administrative purposes, all submissions related to these pediatric postmarketing study commitments must be clearly designated "Required Pediatric Study Commitments."



Submit clinical protocols to your IND for this product. Submit all study final reports to this NDA. In addition, under 21 CFR 314.81(b)(2)(vii) and 314.81(b)(2)(viii), you should include a status summary of each commitment in your annual report to this NDA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies, number of patients entered into each study. All submissions, including supplements, relating to these postmarketing study commitments must be prominently labeled "Postmarketing Study Commitment Protocol," "Postmarketing Study Commitment Correspondence."

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to the Division of Anesthesia, Analgesia, and Rheumatology Products and two copies of both the promotional materials and the package inserts directly to:

Food and Drug Administration Center for Drug Evaluation and Research Division of Drug Marketing, Advertising, and Communications 5901-B Ammendale Road Beltsville, MD 20705-1266

Please submit one market package of the drug product when it is available.

(b)(4)4)
A shelf life of 24 months is granted for this drug product packaged in (b)(4)
<u> </u>
(15):(4) stored at room
<u> </u>

We have not completed validation of the regulatory methods. However, we expect your continued cooperation to resolve any problems that may be identified.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

The MedWatch-to-Manufacturer Program provides manufacturers with copies of serious adverse event reports that are received directly by the FDA. New molecular entities and important new biologics qualify for inclusion for three years after approval. Your firm is eligible to receive copies of reports for this product. To participate in the program, please see the enrollment instructions and program description details at www.fda.gov/medwatch/report/mmp.htm.



NDA 21-928 Page 4

If you have any questions, call Dominic Chiapperino, Regulatory Project Manager, at (301) 796-1183.

Sincerely,

{See appended electronic signature page}

Curtis Rosebraugh, M.D., M.P.H. Deputy Director Office of Drug Evaluation II Center for Drug Evaluation and Research

Enclosures
Package Insert
Patient Package Insert



This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Curtis Rosebraugh 5/10/2006 08:57:37 PM

